MedTrace Logo

Pharmacokinetics of Vildagliptin in Mild, Moderate and Severe Renal Impaired Patients

NCT00818571 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2020-12-17

No results posted yet for this study

Summary

This study assess the pharmacokinetics of vildagliptin in mild, moderate and severe renal impaired patients

Conditions

Interventions

DRUG

Vildagliptin

Mild, moderate and severe renal impaired patients receiving 25 mg vildagliptin once daily

DRUG

Vildagliptin

Mild, moderate and severe renal impaired patients receiving 50 mg vildagliptin once daily

DRUG

Vildagliptin

Matching healthy volunteers receiving 25 mg vildagliptin once daily.

DRUG

Vildagliptin

Matching healthy volunteers receiving 50 mg vildagliptin once daily

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2009-05-31

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00818571 on ClinicalTrials.gov